Immucell (ICCC) Revenue (2010 - 2026)

Immucell (ICCC) has reported Revenue for 17 consecutive years, with $7.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Revenue rose 11.5% year-over-year to $7.2 million; the trailing twelve-month figure through Jun 2026 stood at $26.8 million (down 5.35% YoY), and the FY2025 full-year result was $27.6 million, up 4.34% from the prior year.
• Revenue eased to $7.2 million in Q2 2026 per ICCC's latest filing, from $7.6 million in the prior quarter.
• Across five years, Revenue topped out at $8.1 million in Q1 2025 and bottomed at $3.4 million in Q1 2023.
• Historically, Revenue has averaged $5.8 million across 5 years, with a median of $5.8 million in 2022.
• The sharpest annual moves came in 2023 and 2024: Revenue tumbled 42.55% in 2023, then surged 110.58% in 2024.
• Over 5 years, Revenue stood at $3.9 million in 2022, then surged by 37.99% to $5.4 million in 2023, then jumped by 43.63% to $7.8 million in 2024, then retreated by 1.61% to $7.6 million in 2025, then decreased by 5.77% to $7.2 million in 2026.
• According to Business Quant data, Revenue over the past three periods registered $7.2 million, $7.6 million, and $5.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.